



## Neuland acquires ~197 KL Advanced Intermediates and API Facility near Hyderabad

Hyderabad, India, December 13, 2017 - Neuland Laboratories Limited (NLL) (NSE: NEULANLAB; BSE-Scrip Code:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solution to customers located in around 80 countries, has announced that it has completed the acquisition of the facility of Arch Pharma labs Limited located near Hyderabad, India.

The facility is spread across approx. 12 acres and has a capacity of about 197 KL. It was inspected by the USFDA in 2015. It is a multi-product facility and has five production blocks for advance intermediate and API manufacturing. It also has capabilities for on-site development, analytical method development, quality control laboratory and a pilot plant.

Sucheth Davaluri, Vice Chairman and CEO stated that, 'The organisation is very excited to have acquired these assets. These were much needed to provide flexibility to our operations in the near term and more importantly to meet our growth aspirations over next few years.'

### About Neuland Laboratories Limited

For over 33 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs, and it has filed around 51 U.S. drug master files (USDMFs) and a total of around 650 Regulatory filings in the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit [www.NeulandLabs.com](http://www.NeulandLabs.com).

**If you have any questions or require further information, please feel free to contact**

**IR Department at Neuland**

Tel: +91 40 3021 1600, Email: [ir@neulandlabs.com](mailto:ir@neulandlabs.com)

**Jenna Palmieri, Neuland Laboratories Inc., USA**

Email: [jenna@neulandlabs.com](mailto:jenna@neulandlabs.com)

**Diwakar Pingle, Investor Relations, Christensen**

Tel: +91 22 4215 0210, Email: [dpingle@christensenir.com](mailto:dpingle@christensenir.com)

*Disclaimer: Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*